Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | PPIA | P62937 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20530633 | 0.85 | KMT2A (0.48) | KMT2AEPHX2KCNA5PPIACASP3 | |
| SCHEMBL20530654 | 0.82 | KMT2A (0.46) | KMT2AEPHX2KCNA5PPIACASP3 | |
| SCHEMBL30466812 | 0.82 | KMT2A (0.46) | KMT2AEPHX2KCNA5PPIACASP3 | |
| SCHEMBL20530670 | 0.79 | EPHX2 (0.46) | KMT2AEPHX2 | |
| SCHEMBL30421786 | 0.79 | KMT2A (0.56) | KMT2AEPHX2KCNA5CASP3 | |
| SCHEMBL119384 | 0.79 | KMT2A (0.56) | KMT2AEPHX2KCNA5CASP3 | |
| SCHEMBL525568 | 0.78 | KMT2A (0.58) | KMT2AEPHX2KCNA5CASP3 | |
| SCHEMBL18687752 | 0.76 | KMT2A (0.55) | KMT2AEPHX2PPIACASP3 | |
| SCHEMBL29097418 | 0.75 | KMT2A (0.59) | KMT2AEPHX2PPIACASP3 | |
| SCHEMBL2744610 | 0.75 | KMT2A (0.54) | KMT2AEPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609905-B1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2022-06-08 | — | — | EP | disclosed |
| US-11091514-B2 | Peptide macrocycles and use thereof in the treatment of bacterial infections | HOFFMANN-LA ROCHE INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3609905-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | H. Hoffnabb-La Roche Ag (CH) | 2020-02-19 | — | — | EP | disclosed |
| US-20200040032-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2020-02-06 | — | — | US | disclosed |
| WO-2018189063-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-10-18 | — | — | WO | disclosed |
| EP-3388445-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2018-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091514-B2 | Peptide macrocycles and use thereof in the treatment of bacterial infections | VIP, NPY5R, CXCR3 | KMT2A 4691/4885EPHX2 3891/4885KCNA5 1939/4885 |
| US-20200040032-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | VIP, NPY5R, CXCR3 | KMT2A 4691/4885EPHX2 3891/4885KCNA5 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.